23.10.2014 Views

Answers to Self-Assessment Questions - ACCP

Answers to Self-Assessment Questions - ACCP

Answers to Self-Assessment Questions - ACCP

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

3. Sundaram A, Koukia P, Apovian CM. Nutritional management<br />

of short bowel syndrome in adults. J Clin Gastroenterol<br />

2002;34:207–20.<br />

38. Answer: A<br />

R.C. is at high risk of developing a zinc deficiency<br />

(Answer A) because of the fact that zinc will be lost in high<br />

concentrations from the high-output jejunos<strong>to</strong>my; thus<br />

Answer A is correct. Zinc concentrations in small bowel<br />

output can be as high as 12 mg/L; thus, R.C. may be losing<br />

as much as 18 mg of zinc per day in the jejunos<strong>to</strong>my fluid.<br />

Vitamin B 12<br />

(Answer B), folic acid (Answer C), and copper<br />

(Answer D) are not substantially eliminated in the s<strong>to</strong>ol; thus<br />

R.C.’s risk of zinc deficiency is substantially higher than<br />

the risk of vitamin B 12<br />

, folic acid, or copper deficiencies,<br />

making Answer B, Answer C, and Answer D incorrect.<br />

1. Parrish CR, Krenitsky J, Willcutts K, Radigan AE.<br />

Gastrointestinal disease. In: Gottschlick MM, DeLegge MH,<br />

Mat<strong>to</strong>x T, Mueller C, Worthing<strong>to</strong>n P, eds. The A.S.P.E.N.<br />

Nutrition Support Core Curriculum: A Case-based Approach<br />

– The Adult Patient. Silver Spring, MD: American Society for<br />

Parenteral and Enteral Nutrition, 2007, 508–39.<br />

2. Buchman AL, Scolapio J, Fryer J. AGA technical review<br />

on short bowel syndrome and intestinal transplantation.<br />

Gastroenterology 2003;124:1111–34.<br />

3. Sundaram A, Koukia P, Apovian CM. Nutritional management<br />

of short bowel syndrome in adults. J Clin Gastroenterol<br />

2002;34:207–20.<br />

39. Answer: C<br />

T.C. has developed hypoglycemia (blood glucose<br />

concentration less than 60 mg/dL. The most appropriate<br />

response <strong>to</strong> hypoglycemia after discontinuing the PN when<br />

cycling in a young infant is <strong>to</strong> increase the ramp-down<br />

time; therefore, Answer C (continue <strong>to</strong> ramp up over 1<br />

hour; increase the ramp-down time <strong>to</strong> 2 hours) is the correct<br />

answer. Answer A (do nothing) is not correct. A blood<br />

glucose concentration less than 60 mg/dL can be associated<br />

with complications, including changes in neurodevelopment;<br />

therefore, allowing T.C.’s blood glucose concentration <strong>to</strong><br />

fall <strong>to</strong> 45 mg/dL after discontinuing PN is not appropriate.<br />

Answer B (increase the ramp-up time <strong>to</strong> 2 hours; continue<br />

<strong>to</strong> ramp down over 1 hour) is incorrect because the serum<br />

glucose concentration at the maximum PN infusion rate is<br />

acceptable (90 mg/dL), so no change in the ramp-up time is<br />

needed; also, this option does not address the low glucose<br />

after discontinuing the PN. Answer D (increase both the<br />

ramp-up and ramp-down times <strong>to</strong> 2 hours) could be done;<br />

however, it is not the best answer because the ramp-up time<br />

does not need <strong>to</strong> be changed.<br />

1. Kumpf VJ, Gervasio J. Complications of parenteral nutrition.<br />

In: Gottschlick MM, DeLegge MH, Mat<strong>to</strong>x T, Mueller C,<br />

Worthing<strong>to</strong>n P, eds. The A.S.P.E.N. Nutrition Support Core<br />

Curriculum: A Case-based Approach – The Adult Patient.<br />

Silver Spring, MD: American Society for Parenteral and<br />

Enteral Nutrition, 2007, 323–39.<br />

2. Bendorf K, Friesen CA, Roberts CC. Glucose response <strong>to</strong><br />

discontinuation of parenteral nutrition in patients less than 3<br />

years of age. JPEN: J Parenteral Enteral Nutr 1996;20:120–2.<br />

40. Answer: C<br />

T.C. has been receiving a standard multivitamin<br />

preparation in her PN formulation, but only zinc and<br />

chromium, because the standard trace element preparation<br />

was removed from her PN when her direct bilirubin was<br />

elevated <strong>to</strong> 4 mg/dL. She is receiving about 40% of her<br />

nutrition by the enteral route. Her direct bilirubin in clinic<br />

<strong>to</strong>day is 2.1 mg/dL, and she has a microcytic anemia. The<br />

most appropriate response would be <strong>to</strong> draw a serum iron<br />

panel and ferritin and copper concentrations (Answer C).<br />

Deficiency of both iron and copper can cause microcytic<br />

anemia. T.C. is receiving neither iron nor copper in her<br />

PN formulation; thus she is at risk for deficiency of both.<br />

Therefore, Answer C is correct. Answer A (add standard<br />

pediatric trace elements <strong>to</strong> the PN formulation daily) is<br />

incorrect because T.C.’s direct bilirubin is still elevated,<br />

indicating cholestasis; thus, copper and manganese excretion<br />

may be compromised. The trace element preparation<br />

should not be added unless a deficiency of both copper<br />

and manganese is documented. Answer B (draw a serum<br />

iron panel and ferritin, vitamin B 12<br />

, folate, and copper<br />

concentrations) is incorrect because T.C. has been receiving<br />

both vitamin B 12<br />

and folate daily in her PN formulation, and<br />

these nutrients are associated with macrocytic anemia, not<br />

microcytic anemia. Answer D (start ferrous sulfate drops<br />

orally) is not appropriate at this time because the cause of<br />

the microcytic anemia has not been determined.<br />

1. Chessman KH, Kumpf VJ. <strong>Assessment</strong> of nutrition status and<br />

nutrition requirements. In: Dipiro JT, Talber RL, Yee GC,<br />

Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A<br />

Pathophysiologic Approach, 7 th edition. New York: McGraw<br />

Hill Medical, 2008, 2349–66.<br />

2. Btaiche IF, Khalidi N. Parenteral nutrition-associated liver<br />

complications in children. Pharmacotherapy 2002;22:188–211.<br />

3. Btaiche IF, Khalidi N. Metabolic complications of parenteral<br />

nutrition in adults, part 2. Am J Health Syst Pharm<br />

2004;61:2050–9.<br />

Immunonutrition<br />

41. Answer: D<br />

The best EN intervention for J.B. immediately upon<br />

admission is actually no enteral feeding (Answer D) because<br />

J.B. is hemodynamically unstable and has been incompletely<br />

resuscitated; thus Answer D is correct. However,<br />

hemodynamic instability is a relative contraindication<br />

<strong>to</strong> EN, and some institutions might begin EN in a patient<br />

such as J.B. The immune-enhancing EN formulation with<br />

omega-3 polyunsaturated fatty acids (PUFAs) 8.6 g/L and<br />

antioxidants (Answer B) would be the best response only<br />

if J.B. was hemodynamically stable so that feedings could<br />

be initiated safely, so Answer B is incorrect. Answer A<br />

(immune-enhancing EN formulation with arginine 10 g/L<br />

and omega-3 PUFAs 3.6 g/L) and Answer C (immuneenhancing<br />

EN formulation with arginine 16.3 g/L, glutamine<br />

15 g/L, nucleotides 1.6 g/L, and omega-3 PUFAs 1.7 g/L) are<br />

not correct choices because each contains arginine, which<br />

has been associated with potential harm in patients with<br />

sepsis.<br />

Gastroenterology and Nutrition <strong>Answers</strong><br />

44<br />

Pharmacotherapy <strong>Self</strong>-<strong>Assessment</strong> Program, 6th Edition

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!